We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Ceftazidime-Avibactam as Osteomyelitis Therapy: A Miniseries and Review of the Literature.
- Authors
Mancuso, Alessandro; Pipitò, Luca; Rubino, Raffaella; Distefano, Salvatore Antonino; Mangione, Donatella; Cascio, Antonio
- Abstract
Bone and joint infections (BJIs) caused by multidrug-resistant gram-negative bacteria are becoming a concern due to limited therapeutic options. Although not approved for these indications, an ever-growing amount of evidence supports the efficacy and safety of ceftazidime–avibactam as a therapy for osteomyelitis and prosthetic joint infections. Here, we present three cases of difficult-to-treat resistant Pseudomonas aeruginosa osteomyelitis that were successfully treated with ceftazidime–avibactam alone or in combination therapy with fosfomycin and amikacin. Ceftazidime–avibactam was prescribed at a daily dose of 2.5 g every 8 h for 42 days in all cases. One potential drug-related adverse effect was observed, i.e., Clostridioides difficile infection, which occurred after fourteen days of treatment with ceftazidime–avibactam.
- Subjects
LITERATURE reviews; OSTEOMYELITIS; ARTIFICIAL joints; CLOSTRIDIOIDES difficile; JOINT infections; GRAM-negative bacteria; PSEUDOMONAS aeruginosa
- Publication
Antibiotics (2079-6382), 2023, Vol 12, Issue 8, p1328
- ISSN
2079-6382
- Publication type
Article
- DOI
10.3390/antibiotics12081328